Objective: Two of the guideline-concordant therapies for severe community-acquired pneumonia are either a beta-lactam and fluoroquinolone or beta-lactam and macrolide. However it is unclear if there is a benefit for one vs. the other for elderly patients with severe community-acquired pneumonia.
P neumonia is the eighth leading cause of death in the United
States and is the leading infectious cause of death. Although mortality dropped precipitously with the advent of antimicrobial therapy, since 1950 mortality has been relatively stable despite the development of other interventions. Today it remains a leading cause of mortality with >50,000 deaths annually (1) .
In response to the major impact of pneumonia, a number of prominent organizations, including the American Thoracic Society and Infectious Diseases Society of America have published clinical practice guidelines for community-acquired pneumonia (2) (3) (4) (5) (6) (7) . Previous studies have suggested that the empiric use of beta-lactams alone is associated with increased mortality and that the use of macrolides for patients with community-acquired pneumonia, and no risk factors pneumonia due to Pseudomonas aeruginosa or methicillin resistant Staphylococcus aureus, is associated with improved outcomes (8) (9) (10) (11) (12) (13) . In addition, we previously demonstrated an association, for patients hospitalized with severe community acquired pneumonia, between the empiric use of a beta-lactam with a fluoroquinolone and increased 30-day mortality (14) .
Despite this, there have been few published studies examining guidelineconcordant therapy with the combination of a beta-lactam plus a fluoroquinolone (BL+F) as compared to guideline concordant therapy with a beta-lactam plus a macrolide (BL+M) for patients hospitalized with severe community-acquired pneumonia. Therefore, the aim of this study was to examine the association between these antibiotic treatment regimens and important clinical outcomes, including 30-day mortality and length of hospital stay for patients > 65 yrs of age hospitalized with severe, community-acquired pneumonia.
METHODS
We conducted a population-based cohort study utilizing the administrative databases of the Department of Veterans Affairs (VA We also obtained information on comorbid conditions from inpatient and outpatient administrative data. We used Charlson's comorbidity methodology to classify other preexisting comorbid conditions, both individually and as a composite score (15, 16 ). Charlson's comorbidity system includes 19 comorbid conditions, which are classified using International Classification of Diseases, -Ninth Edition codes from prior outpatient and inpatient encounters (17) . For severity of illness we assessed the need for mechanical ventilation and/or vasopressors within 48 hrs of admission.
Antimicrobial Therapy. For this study, patients were included in the BL+F group if they received at least one beta-lactam and at least one fluoroquinolone, but did not receive any macrolides within 48 hrs of admission. Similarly, the BL+M cohort was made 
Pre-existing comorbid conditions
Myocardial infarction 97 (7) 33 (7) .95
Congestive heart failure 397 (27) 136 (27) .94
Peripheral vascular disease 223 (15) 72 (14) .60
Cerebrovascular disease 242 (16) 102 (20 Outcomes. Outcomes included 30-day mortality and length of hospital stay. We chose to examine mortality at 30-days, as previous research has demonstrated that 30-day mortality is due primarily to pneumonia rather than comorbid conditions (18, 19) . Mortality was assessed through October 1, 2007, using the VA vital status file. Previous studies have demonstrated that this methodology has a sensitivity of ~98% for veterans' deaths (20) . Length of stay is also of additional interest in that it may represent a potential indicator of both inpatient treatment costs and time to clinical stability (21) .
Statistical Analysis. Statistical significance was defined as two-tailed p ≤ .05. We examined univariate relationships using Student's t tests for the continuous variables, and chi-square tests for the binary variables.
A propensity score technique was used to balance covariates associated with antimicrobial therapy between groups. This propensity score was derived from a logistic regression model using the dichotomous treatment indicator as the predictor variable. We included those variables that were statistically significant in univariate analyses (two-tailed p ≤ .05) or that we hypothesized a priori would be associated with outcomes or with the treatments of interest. The covariates used in the propensity score model were age, sex, race, marital status, comorbid conditions, priority group (a marker for socioeconomic status), current tobacco cessation attempts, alcohol or drug abuse, the number of primary care visits during the year prior to admission, the need for mechanical ventilation, and the need for vasopressors.
For our primary analyses, we used multilevel regression models (logistic or Poisson as appropriate) to examine the effect of BL+F vs. BL+M (reference group) on each of the outcomes after adjusting for an ordered categorical variable based on quintile stratification of the propensity score with admitting hospital as a second level variable. As a secondary analysis, we included only those subjects who received antipseudomonal therapy and repeated the multilevel regression analysis.
Analyses were performed using STATA 10 (StataCorp LP, College Station, TX).
RESULTS
The cohort was composed of 1,989 subjects who met the inclusion and exclusion criteria with a mean age of 74 yrs (SD 6.5) and 98.5% were male. The majority of the cohort was white (81.5%), with black race and Hispanic ethnicity making up 12.2% and 5%, respectively. The most common comorbid conditions were diabetes (34%), congestive heart failure (27%), and malignant neoplasms (20%).
The study cohort had 30-day all-cause mortality of 25.6%. Table 1 shows factors by vital status at 30-days after admission. Those alive at 30 days had a lower mean age (73.6 vs. 75.3, p < .001), a lower rate of liver disease (0.5% vs. 2%, p = .02), and a lower rate of malignant neoplasms (19% vs. 23%, p = .02); but also a higher rate of smoking cessation efforts (37% vs. 29%). Survivors had a significantly lower rate of mechanical ventilation (35% vs. 51%, p < .001) and vasopressor use (20% vs. 35%, p = .005).
We also compared subjects by treatment type ( Table 2) . The clinical and demographic characteristics of the BL+F and BL+M groups were quite similar. Patients in the BL+F group had a slightly higher average age (74.6 yrs vs. 73.6 yrs, p < .001) and a lower rate of current attempts at smoking cessation (31% vs. 38%, p = .003). The BL+F group also had a lower percentage of white patients (78% vs. 84%, p < .001) and a higher percentage of black patients (15% vs. 10%, p < .001). Although mortality was similar between treatment types (27% for BL+F vs. 24% for BL+M, p = .11), patients treated with BL+F had a significantly longer length of hospital stay (21.0 days vs. 15.9 days, p < .001) ( Table 2) .
After adjusting for potential confounding factors (Table 3) , 30-day mortality was similar between treatment 
DISCUSSION
In our study, the use of BL+F was associated with a longer average length of hospital stay compared to those treated with BL+M; however, there were no significant differences found in 30-day mortality. Clinical guidelines published by major medical societies represent valuable tools for maximizing the efficacy of medical interventions, and thus, reducing the complications associated with pneumonia (8, 19, 22) . Despite this, our results support previous evidence demonstrating that treatment with BL+ M may be the more preferable choice (23) . These results raise questions regarding the current recommendations that do not specify which antibiotic combinations (BL+M or BL+F) are the more preferable treatment for severe community-acquired pneumonia. Therefore, there is a need for randomized controlled trials that assess the relative efficacy of the specific antimicrobial therapies recommended by these guidelines.
Several studies in the past have found that the use of a BL+M is significantly associated with lower mortality (8) (9) (10) 13) . On the other hand, other studies have demonstrated that monotherapy with beta-lactam is associated with worse clinical outcomes (8, 10, 13, 24) . There are a few studies that have compared the antibiotic combination of BL+F with antibiotic combination BL+M (9, 13, 14, 25) , and there were no significant differences found, except for one study. However, many of these studies had significant limitations (i.e., the lack of multivariable analyses, or too few subjects) to be able to appropriately examine this antimicrobial combination.
It seems unlikely that the difference in length of hospital stay between the two antibiotic treatment combinations stems from a difference in bacterial coverage. One possible explanation for the improved outcomes associated with the use of macrolides may be due to their previously demonstrated anti-inflammatory activity (26) (27) (28) (29) . This is supported by the previously demonstrated role of cytokines as mediators of acute respiratory distress syndrome, sepsis, and a number of pneumonia's negative prognostic factors (30) (31) (32) (33) (34) (35) . Therefore, we hypothesize that an antibiotic regimen, which includes a macrolide, will be more potentially protective when compared to antibiotic regimens without a macrolide. Another potential explanation is that recent studies suggest that fluoroquinolone use in intensive care unit patients is associated with increased risk for hospital-acquired multidrug resistant pathogens, which may also increase mortality and length of stay (36, 37) .
There are a number of limitations to our analysis. The largest limitation was reliance on administrative data. Therefore, information such as the Acute Physiology and Chronic Health Evaluation score, duration of mechanical information, and inhospital complications (e.g., Clostridium difficile infections) were not available. We feel confident that our inclusion criteria requiring intensive care unit level of care during the first 48 hrs of admission allowed us to identify subjects with comparable levels of illness. In addition, due to the design of the primary study, we did not have information regarding duration of antibiotic therapy nor subsequent antibiotic regimes. Also, <2% of the VA patient population is female, which limits its generalizability. Additionally, male veterans may not be representative of the population as a whole. Another limitation is the inability to adjust for microbiology and antimicrobial resistance patterns at each patient's place of treatment. While these factors could impact the efficacy of the two antibiotic regimes, the use of data from the entire VA healthcare system makes it likely that results represent the general population rather than the nuances of a specific institution. Lastly, another limitation was that we were unable to determine if the reason for the use of one antibiotic combination vs. the other was due to increased severity of illness. Furthermore, as with any nonrandomized study, we are unable to state conclusively that differences in length of stay are due to the antibiotic received and not differences in patient characteristics at baseline.
In conclusion, although we did not find a significant difference in mortality between patients treated with BL+F vs. BL+M, there were significant differences in length of hospital stay, which is potentially associated with higher costs of healthcare and resource utilization. Therefore, clinically appropriate clinicians should preferably use BL+M for the treatment of severe community-acquired pneumonia. Further research is needed to determine which antimicrobial regimens provide the best outcomes for patients with severe community-acquired pneumonia. 
